160 related articles for article (PubMed ID: 26789842)
1. A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy.
Deshpande A; Toshniwal H; Joshi S; Jani RH
PLoS One; 2016; 11(1):e0146222. PubMed ID: 26789842
[TBL] [Abstract][Full Text] [Related]
2. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI).
Jani RH; Pai V; Jha P; Jariwala G; Mukhopadhyay S; Bhansali A; Joshi S
Diabetes Technol Ther; 2014 Feb; 16(2):63-71. PubMed ID: 24138536
[TBL] [Abstract][Full Text] [Related]
3. Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
Krishnappa M; Patil K; Parmar K; Trivedi P; Mody N; Shah C; Faldu K; Maroo S; ; Parmar D
Cardiovasc Diabetol; 2020 Jun; 19(1):93. PubMed ID: 32560724
[TBL] [Abstract][Full Text] [Related]
4. Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial.
Rodriguez-Gutierrez R; González JG; Parmar D; Shaikh F; Cruz-López P
J Lipid Res; 2022 Jul; 63(7):100233. PubMed ID: 35605678
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of saroglitazar in managing hypertriglyceridemia in type-2 diabetes: A meta-analysis.
Dutta D; Bhattacharya S; Surana V; Aggarwal S; Singla R; Khandelwal D; Sharma M
Diabetes Metab Syndr; 2020; 14(6):1759-1768. PubMed ID: 32937280
[TBL] [Abstract][Full Text] [Related]
6. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.
Alaupovic P; Heinonen T; Shurzinske L; Black DM
Atherosclerosis; 1997 Aug; 133(1):123-33. PubMed ID: 9258416
[TBL] [Abstract][Full Text] [Related]
7. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
Gawrieh S; Noureddin M; Loo N; Mohseni R; Awasty V; Cusi K; Kowdley KV; Lai M; Schiff E; Parmar D; Patel P; Chalasani N
Hepatology; 2021 Oct; 74(4):1809-1824. PubMed ID: 33811367
[TBL] [Abstract][Full Text] [Related]
8. Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial.
Jain N; Bhansali S; Kurpad AV; Hawkins M; Sharma A; Kaur S; Rastogi A; Bhansali A
Sci Rep; 2019 Dec; 9(1):19017. PubMed ID: 31831868
[TBL] [Abstract][Full Text] [Related]
9. A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V).
Pai V; Paneerselvam A; Mukhopadhyay S; Bhansali A; Kamath D; Shankar V; Gambhire D; Jani RH; Joshi S; Patel P
J Diabetes Sci Technol; 2014 Jan; 8(1):132-141. PubMed ID: 24876549
[TBL] [Abstract][Full Text] [Related]
10. Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects.
Patel MR; Kansagra KA; Parikh DP; Parmar DV; Patel HB; Soni MM; Patil US; Patel HV; Patel JA; Gujarathi SS; Parmar KV; Srinivas NR
Clin Drug Investig; 2018 Jan; 38(1):57-65. PubMed ID: 29022212
[TBL] [Abstract][Full Text] [Related]
11. Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients.
Shetty SR; Kumar S; Mathur RP; Sharma KH; Jaiswal AD
Indian Heart J; 2015; 67(1):23-6. PubMed ID: 25820046
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.
McKenney JM; McCormick LS; Weiss S; Koren M; Kafonek S; Black DM
Am J Med; 1998 Feb; 104(2):137-43. PubMed ID: 9528731
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
Bakker-Arkema RG; Davidson MH; Goldstein RJ; Davignon J; Isaacsohn JL; Weiss SR; Keilson LM; Brown WV; Miller VT; Shurzinske LJ; Black DM
JAMA; 1996 Jan; 275(2):128-33. PubMed ID: 8531308
[TBL] [Abstract][Full Text] [Related]
14. Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy.
Rao A; D'Amico S; Balasubramanyam A; Maldonado M
Am J Med Sci; 2004 Jun; 327(6):315-8. PubMed ID: 15201643
[TBL] [Abstract][Full Text] [Related]
15. A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary Cholangitis.
Vuppalanchi R; González-Huezo MS; Payan-Olivas R; Muñoz-Espinosa LE; Shaikh F; Pio Cruz-Lopez JL; Parmar D
Clin Transl Gastroenterol; 2021 Mar; 12(4):e00327. PubMed ID: 33769355
[TBL] [Abstract][Full Text] [Related]
16. Postprandial remnant-like lipoproteins in hypertriglyceridemia.
Ooi TC; Cousins M; Ooi DS; Steiner G; Uffelman KD; Nakajima K; Simo IE
J Clin Endocrinol Metab; 2001 Jul; 86(7):3134-42. PubMed ID: 11443178
[TBL] [Abstract][Full Text] [Related]
17. N-3 fatty acids for hypertriglyceridemia in patients taking second-generation antipsychotics.
Fetter JC; Brunette M; Green AI
Clin Schizophr Relat Psychoses; 2013; 7(2):73-77A. PubMed ID: 23367502
[TBL] [Abstract][Full Text] [Related]
18. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia.
Wohl DA; Tien HC; Busby M; Cunningham C; Macintosh B; Napravnik S; Danan E; Donovan K; Hossenipour M; Simpson RJ
Clin Infect Dis; 2005 Nov; 41(10):1498-504. PubMed ID: 16231263
[TBL] [Abstract][Full Text] [Related]
19. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
20. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
Hogue JC; Lamarche B; Deshaies Y; Tremblay AJ; Bergeron J; Gagné C; Couture P
Metabolism; 2008 Feb; 57(2):246-54. PubMed ID: 18191056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
